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Abstract
Tetherin (BST2/CD317) is a viral restriction factor that anchors
enveloped viruses to host cells and limits viral spread. The HIV-1 Vpu
accessory protein counteracts tetherin by decreasing its cell surface
expression and targeting it for ubiquitin-dependent endolysosomal
degradation. Although the Vpu-mediated downregulation of tetherin
has been extensively studied, the molecular details are not completely
elucidated. We therefore used a forward genetic screen in human hap-
loid KBM7 cells to identify novel genes required for tetherin trafﬁck-
ing. Our screen identiﬁed WDR81 as a novel gene required for tetherin
trafﬁcking and degradation in both the presence and absence of Vpu.
WDR81 is a BEACH-domain containing protein that is also required
for the degradation of EGF-stimulated epidermal growth factor recep-
tor (EGFR) and functions in a complex with the WDR91 protein. In the
absence of WDR81 the endolysosomal compartment appears swollen,
with enlarged early and late endosomes and reduced delivery of endocy-
tosed dextran to cathepsin-active lysosomes. Our data suggest a role for
the WDR81-WDR91 complex in the fusion of endolysosomal compart-
ments and the absence of WDR81 leads to impaired receptor trafﬁcking
and degradation.
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As obligate intracellular parasites, viruses have evolved
multiple strategies to manipulate host cellular pathways, to
enable their replication and evade immune detection. Con-
versely,mammalian cells have developed restriction factors
that limit or prevent different stages of viral replication.
The study of how viruses target host factors has provided
key insights into our understanding of viral pathogenesis
as well as fundamental aspects of host cell biology.
A good example of this is the HIV1-Vpu mediated
downregulation of the viral restriction factor, teth-
erin (BST2/CD317). Tetherin inhibits the release of a
wide spectrum of enveloped viruses, including human
immunodeficiency virus (HIV) and Ebola, from infected
cells (1–13). Tetherin achieves this by targeting the lipid
bilayer of the viral envelope, a molecular component that
cannot be mutated or eliminated. Tetherin is an inter-
feron inducible, transmembrane protein with an unusual
topology, that is key to its antiviral function. It encodes an
extended extra-cellular alpha helix with both extremities
embedded in cellular membranes using different anchors:
an N-terminal transmembrane domain and a C-terminal
glycosylphosphatidyl-inositol (GPI) anchor (14–17). This
allows tetherin to form disulphide linked homodimers
and anchor virions to cellular membranes through its
terminal domains (17–19). Beyond limiting the spread of
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viruses, the tetherin-mediated accumulation of virions at
the plasma membrane (PM) enhances antibody opson-
isation (20–23), leads to virion endocytosis (1,24) and
can induce proinflammatory NF-kB signalling (25–27).
Tetherin localizes not only to PM lipid rafts but also to
endocytic compartments and the trans-Golgi network
(TGN) (14). Its N-terminal cytoplasmic tail contains the
YDYCRV endocytic motif which binds the AP1 and AP2
clathrin adaptors and facilitates the endocytic recycling of
tetherin via the TGN (28).
The HIV-1 encoded accessory protein Vpu counteracts the
inhibitory effects of tetherin, the HIV-1 receptor CD4 and
the amino acid transporter SNAT1. Vpu uses its DSGNES
phosphodegron to recruit the same SCFβTrCP2 E3 ubiqui-
tin ligase complex to facilitate the ubiquitination of tetherin
(29–32), CD4 (33) and SNAT1 (34), but targets the differ-
ent proteins in distinct compartments and enhances their
degradation via different mechanisms. Vpu traps newly
synthesized CD4 in the ER and promotes its degrada-
tion through ER-associated protein degradation (ERAD)
(33,35). In contrast to CD4 degradation, tetherin antago-
nism is abolished by artificial retention of Vpu in the ER
(36) asVpu targets tetherin in a post-ER compartment (36).
The tetherin–Vpu interaction occurs via their respective
transmembrane domains and leads to a reduction of teth-
erin levels at the cell surface (19,37,38). Nevertheless, Vpu
has little effect on the rate of PM endocytosis of tetherin
(39–41) but rather interferes with the delivery of newly
synthesized tetherin to the PM and with tetherin recycling
via the TGN (39,41). Consistent with the notion that Vpu
prevents access of tetherin to the PM is the observation that
both tetherin and Vpu colocalize mainly to TGN compart-
ments in HIV-infected cells (42,43). Tetherin downregu-
lation from the PM relies on clathrin-mediated endocy-
tosis (40,43), Rab7 GTPase (44) and the endosomal sort-
ing complex required for transport (ESCRT) proteins HRS
(45), TSG101 (45) and UBAP1 (46).
Despite significant advances in our mechanistic under-
standing of Vpu-mediated antagonism of tetherin,
the molecular details are not fully elucidated (12,47).
For example, there is controversy surrounding Vpu’s
E59XXXLV64 motif. EXXXLV mutants can bind tetherin,
the SCFβTrCP2 complex andHRS and yet have limited capa-
bility in decreasing cell surface expression or degradation
of tetherin (48). Furthermore, both Vpu EXXXLVmutants
and tetherin are present at the PM and both are incorpo-
rated in nascent virions (48). This suggested that Vpu’s
E59XXXLV64 motif might facilitate interaction with other,
unknown components of the cellular machinery. More-
over, the requirement for SCFβTrCP2 in the Vpu-mediated
downregulation of PM tetherin has been much debated
(30,31,37,41,49). A recent study addressed these issues and
showed that SCFβTrCP2 is essential for the Vpu-mediated
degradation of tetherin but dispensable for tetherin down-
regulation from the PM in HIV-1 infected cells (50).
Furthermore, phosphorylation of Vpu’s DSGNES motif
serves not only for the recruitment of SCFβTrCP2, but is
also required along with the intact E59XXXLV64 motif for
binding to either clathrin adaptors AP-1 or AP-2 (50,51).
To further understand the molecular machinery required
for Vpu-mediated tetherin downregulation and degrada-
tion, we used a novel approach in the form of a for-
ward genetic screen in Vpu-expressing KBM7 cells. This
methodology has proven successful in enabling the iden-
tification and characterization of novel genes required for
viral entry (52) as well as intracellular viral evasion path-
ways (53–55). Our screen identified WDR81, a poorly
characterized BEACH domain containing protein we find
to be required for tetherin trafficking and degradation in
both the presence and absence of Vpu. Upon WDR81
depletion, tetherin accumulates in enlarged endocytic vesi-
cles/compartments. Furthermore, our data show that the
loss of WDR81 delays the delivery of endocytosed fluid
phase cargo to lysosomes and inhibits degradation of the
EGFR.We find thatWDR81 forms a complexwithWDR91
and this interaction is critical for function. Therefore,
by studying tetherin trafficking in mammalian cells, we
have identified aWDR81-WDR91 complex responsible for
maintaining themorphology and function of the endolyso-
somal pathway.
Results
A haploid genetic screen identiﬁes a requirement
for WDR81 in the Vpu-mediated downregulation
of tetherin
To identify novel host factors required for the
HIV1-Vpu-mediated downregulation and degradation
of tetherin and CD4, we performed a forward genetic
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screen in human near-haploid KBM7 cells. We predicted
that disruption of a gene essential for Vpu function
would interfere with tetherin or CD4 downregulation
and increase their cell surface expression, resulting in
tetherinhigh and/or CD4high cells (Figure 1A). We created
a cell line expressing HIV-1 NL4.3 Vpu internal ribosome
entry site (IRES) CFP (Vpu-CFP) (Figure S1A, Supporting
Information) and selected clones with low cell-surface
expression of endogenous tetherin and CD4. A total of
three Vpu-CFP clones were pooled and transduced with
a gene-trap retrovirus, at an MOI of 1 to prevent mul-
tiple retroviral gene-trap mutations per cell. Seven days
post-mutagenesis, rare Vpu-KBM7 cells that were either
tetherinhighCFPhigh or CD4highCFPhigh (Figure 1A) were
selected by fluorescence-activated cell sorting (FACS). The
sorting gates were designed to avoid rare cells which have
lost Vpu expression and thus became both tetherinhigh and
CD4high (Figure S1B). Seven days after the first selection,
the CD4high population underwent a second FACS enrich-
ment, which allowed visualization of a CD4high tetherinlow
cell population (Figure 1A), from which genomic DNA
was extracted. The retroviral gene-trap integration sites
from this enriched CD4high population were sequenced
and mapped back to the genome resulting in the identifi-
cation of three genes that were significantly enriched for
inactivating insertions compared to an unselected control
population (53): βTrCP2 (FBXW11), CUL1 and UBE2M
(Figure S1C). The discovery of these genes validated our
genetic approach as they are all members of the SCFβTrCP2
E3 ubiquitin ligase complex, known to be recruited by
Vpu to facilitate the ubiquitination and subsequent degra-
dation of CD4 (29–33). Although depletion of βTrCP2
in Vpu-expressing KBM7 cells (Figure S1D) restores PM
levels of CD4, cell surface expression of tetherin is not res-
cued, explaining why component genes of the SCFβTrCP2
complex were not identified as hits in the tetherinhigh
screen.These findings are in agreement with a recent study
that found βTrCP2 to be dispensable for the Vpu-mediated
downregulation of tetherin from the PM (50).We observed
the same effect, with a full rescue of PM CD4 levels but no
restoration of cell surface tetherin, when depleting βTrCP2
in Vpu-expressing CEMT4 cells, a human leukemic CD4+
T-cell line used in HIV studies (Figure S1E). CEMT4 cells
appear more susceptible to CRISPR-Cas9-mediated edit-
ing, showing better knock-out (KO) efficiency than KBM7
cells (compare Figure S1D with E and data not shown) and
were thus used for the validation of further hits.
A second FACS enrichment on the tetherinhigh popula-
tion was unsuccessful as following selection the majority
of the sorted cells died. Genomic DNA was therefore
extracted from cells recovered from the first tetherinhigh
sort (Figure 1A). Mapping of these gene-trap integra-
tion sites identified four genes: VPS33a, VPS39, TSC2
and WDR81 (Figure 1B). VPS33a and VPS39 are known
components of the homotypic fusion and vacuole protein
sorting complex (HOPS) (56–58). The HOPS complex
is essential for endosomal maturation (59), delivery of
cargo to lysosomes (60,61) and fusion of autophagosomes
with late endosomes/lysosomes (62). TSC2 is a negative
regulator of the mTORC1 complex [reviewed in (63)]
and has also been described as a Rab5 GTPase activating
protein (GAP) (64,65). We chose to focus on the top hit,
WDR81, a large and poorly characterized gene which
had 44 independent trapping integrations in transcript 1
(ENST00000409644) (Figure 1C).
To verify the requirement forWDR81 in the Vpu-mediated
downregulation of tetherin, we used the CRISPR-Cas9
system to KO WDR81 in CEMT4 cells. We confirmed
depletion of WDR81 in the sgRNA-targeted CEMT4
cell population, as the predicted 210-kDa WDR81 band
detected in control CEMT4 cells was markedly reduced
in the WDR81KO mixed cell population (Figure 2A).
Immunoblot analysis showed that the Vpu-mediated
decrease in tetherin levels seen in Vpu-CEMT4 cells
(Figure 2A, lane 2 and three replicates quantified in B)
was rescued following depletion of WDR81 (Figure 2A,
lane 3 and three replicates quantified in B). Furthermore,
even in the absence of Vpu, depletion of WDR81 caused
a significant increase in tetherin levels (Figure 2A, lane
4, and three replicates quantified in B). Interestingly, the
marked increase in the intracellular tetherin pool resulted
in only a modest rescue (1.6-fold) of cell surface tetherin
in WDR81-depleted, Vpu-CEMT4s (Figure S2A and three
replicates quantified in B), suggesting that accumulation of
cellular tetherin occurs predominantly in an intracellular
compartment.
To identify where tetherin accumulates in the absence
of WDR81, we generated HeLa cell clones deficient in
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Figure 1: A haploid genetic screen identiﬁes a requirement for WDR81 in the Vpu-mediated downregulation of
tetherin. A) Near-haploid Vpu-KBM7 cell clones were mutagenised with gene-trap retroviruses and rare CD4high cells selected by
two sequential rounds of FACS. Rare tetherinhigh cells were selected by one round of FACS. Approximate sorting gates are indicated.
Schematic drawings of cells at various stages of the genetic screen are shown above or below respective scatterplots. Black spikes
represent CD4, red spikes represent tetherin. B) Bubble plot illustrating the hits from the tetherinhigh screen. Bubble size is proportional
to the number of independent inactivating gene-trap integrations identiﬁed (shown in brackets). C) Sequencing of retroviral insertion
sites in the selected tetherinhigh population revealed 44 independent inactivating insertions (red triangles) in the WDR81 gene on
chromosome 17. Grey rectangles represent exons.
WDR81 (HeLa-WDR81KO)±Vpu. Two independent
sgRNAs targetingWDR81 exon 4 and 5 generatedWDR81
deficient clones as confirmed using immunoblot analysis
(Figure 2C). Vpuwas stably expressed inWDR81 knockout
clones and control HeLa cells and, as expected, both flow
cytometry and confocal immunofluorescence microscopy
confirmed that both the cell surface and the intracellular
pool of tetherin was reduced in Vpu-expressing HeLa cells
Trafﬁc 2016; 17: 940–958 943
Rapiteanu et al.
Figure 2: Legend on next page.
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(Figure S2C and D). In the two WDR81-knockout clones,
tetherin accumulated in swollen, perinuclear, vesicular
compartments in both the presence and absence of Vpu
(Figure 2D). To confirm this observation and exclude
possible artefacts associated with stable Cas9 and sgRNA
expression, we carried out a rescue experiment. First, we
created a further WDR81KO HeLa cell line by transient
expression of Cas9 and WDR81-sgRNA #1 (targeting
WDR81 exon 5). Single cell clones were selected and loss
of WDR81 again confirmed (Figure 2E). The intracellular
accumulation of tetherin seen in the WDR81KO clone
was rescued by stable expression of WDR81 [untagged
or N-terminus 2×HA tagged (Figure 2E)], confirming
that loss of WDR81 was responsible for the observed
phenotype (Figure 2F). Furthermore, the accumulation
of tetherin in swollen vesicular compartments was only
seen in those cells not complemented by 2×HA-WDR81
(Figure 2G). Thus, we validated WDR81 as required for
tetherin trafficking and degradation.
WDR81 is a BEACH domain containing protein that
associates with endolysosomal membranes
WDR81 is a 1941 amino acid, Beach (after ‘Beige and
Chediak–Higashi’) domain containing protein (BDCP)
with five C-terminal WD40 domains (Figure 3A). Of the
nine known human BDCPs, LYST is the best studied and
is mutated in Chediak–Higashi syndrome (CHS) (66,67).
BDCPs are cytoplasmic, membrane-associated proteins
known to function in endolysosomal trafficking [reviewed
in (68)]. Although initially described as a transmembrane,
mitochondrial protein (69,70), TMHMM2.0 analysis of
WDR81 showed no characteristic features of an integral
membrane protein (71), and ultracentrifugation of cell
homogenates did not support this assertion (Figure 3B).
Indeed, ultracentrifugation of cell homogenates showed
that WDR81 was predominantly found in the soluble frac-
tion at neutral pH and entirely in the soluble fraction at
high pH (Figure 3B).This suggests thatWDR81 is a cytoso-
lic protein which may associate with membranes.
We next sought to identify the compartment(s) with
which WDR81 associates. Exogenous expression of
2×HA-WDR81 in WDR81KO cells rescues the accu-
mulation of tetherin from enlarged perinuclear vesicles
(Figure 2F and G) but leads to significantly higher pro-
tein levels as compared to wild-type cells (Figure 2E)
which limit sub-cellular localization studies. Extraction
of non-membrane-associated proteins by a brief saponin
wash prior to fixation allowed us to image the mem-
brane bound fraction of 2×HA-WDR81. We found that
membrane-associated 2×HA-WDR81 partially colocalizes
with both early EEA1 positive and late LAMP1 positive
endocytic compartments (Figure 3C). The remaining
WDR81 pool observed in Figure 3C probably reflects
remaining cytosolic protein due to incomplete extraction
and/or other membrane-associated protein. Nevertheless,
taken together, Figures 3B and C suggest that WDR81
associates with endolysosomal membranes.
WDR81 modulates endolysosomal morphology and the
delivery of endocytosed cargo to late endo-lysosomal
compartments
Because tetherin traffics through the endolysosomal path-
way, we wanted to identify the site of tetherin accumula-
tion in the absence of WDR81. Our prediction that the
swollen tetherin positive vesicles seen inWDR81 knockout
cells were enlarged endosomal and/or lysosomal compart-
ments was confirmed by the accessibility of these vesicles to
Figure 2: Depletion of WDR81 results in accumulation of tetherin in vesicular compartments in both the presence
and absence of Vpu. A) WDR81 and tetherin expression was assessed by immunoblotting control and WDR81 depleted CEMT4
cells± Vpu. B) Tetherin levels from three independent experiments using cells in ‘A’ were quantiﬁed with Image J and normalized by
loading. Histograms represent mean normalized tetherin signal ±SEM. *p≤ 0.05, **p≤ 0.01, ***p≤ 0.001. C) WDR81 expression
was assessed by immunoblot in HeLa cell clones± Vpu stably expressing Cas9 and two independent WDR81 speciﬁc sgRNAs. D)
Confocal microscopy images of endogenous tetherin using cells in ‘C’. Cell edges in Vpu expressing cells are outlined in red. E) HeLa
cells were depleted of WDR81 by transient expression of Cas9 and WDR81 sgRNA#1 and single cell cloned. Exogenous expression
of 2×HA-WDR81 in these WDR81KO clones was analysed by immunoblot. F) Immunostaining of endogenous tetherin in control,
WDR81KO clones and WDR81KO clones genetically complemented with exogenous WDR81 or 2×HA-WDR81. G) Immunostaining of
tetherin and 2HA-WDR81 in genetically complemented WDR81KO cells (prior to blasticidin selection). All scale bars represent 10 μm.
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Figure 3: WDR81 is a BEACH domain containing protein that associates with endolysosomal membranes. A) Schematic
view of WDR81 and LYST protein domains. B) Ultracentrifugation of HeLa cell homogenates in neutral pH TBS buffer and highly
basic sodium carbonate buffer. WCE, whole cell extract. C) Immunostaining of 2×HA-WDR81 and EEA1 or LAMP1 in cytosol
extracted HeLa cells. WDR81KO cells complemented with exogenous 2xHA-WDR81 were permeabilized with saponin to extract
non-membrane-associated proteins and ﬁxed before immunolabelling. Scale bars: 5 μm.
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endocytosed, fluid phase dextran (Figure 4A). To further
characterize these swollen endolysosomal compartments
in WDR81 depleted cells we examined the distribution
of known endolysosomal markers. Confocal microscopy
images showed that swollen compartments were positive
for early endosomal markers (EEA1 and Rab5) (Figure 4B)
and late endosomal/lysosomal markers (CD63, LAMP1
and Cathepsin D) (Figure 4C). Thus, WDR81 is required
for maintaining the correct morphology of both early and
late endocytic compartments.
Our findings of impaired tetherin degradation, together
with the accumulation of tetherin in swollen endolysoso-
mal compartments in the absence of WDR81 (Figure 1D)
questioned whether the loss of WDR81 affected lysosomal
acidification or trafficking of lysosomal proteases such that
the degradative capacity of the lysosomal compartment is
impaired. Live-cell confocalmicroscopy of LysoSensor Yel-
low/Blue DND-160 labelled WDR81KO cells showed that
some of the swollen compartments were acidic (Figure
S3A and quantified in B). The presence of both neutral
and acidic swollen compartments is consistent with the
idea that depletion of WDR81 causes the enlargement of
both early (neutral) and late (acidic) endosomes. Quan-
tification of yellow/blue ratios revealed that depletion of
WDR81 causes higher acidification of late endosomal com-
partments (Figure S3B). Furthermore, swollen compart-
ments were readily labelled by the membrane permeable,
cresyl violet-conjugatedMagic Red substrate for Cathepsin
B (Figure 4D). Together these experiments suggest that in
the absence ofWDR81, these swollen endolysosomal com-
partments are both acidified and contain functional lyso-
somal proteases.
Because the degradative capacity of late endolysosomal
compartments appeared unimpaired in WDR81-depleted
cells, we predicted that tetherin accumulation should
occur in early compartments. To test this, we fluorescently
labelled both control and WDR81KO cells for tetherin
together with the early endosomalmarker EEA1 and/or the
late endosomal/lysosomal marker LAMP1. In wild-type
HeLa cells, the intracellular pool of tetherin localizes
predominantly within EEA1 positive vesicles [Figure S3C
and (45)] but not within LAMP1 positive vesicles (Figure
S3D). In the absence of WDR81, the early EEA1 positive
and late LAMP1 positive compartments are distinct and
tetherin accumulation is predominantly seen within early,
swollen EEA1 positive vesicles (Figure 4E and S3C) but not
within late, swollen LAMP1 positive vesicles (Figure 4E
and S3D).
Taken together, the data in Figures 2D and 4B–E suggest
that WDR81 depletion abolishes maturation of endosomal
compartments and/or impairs the delivery of cargo from
early to late endolysosomal compartments. To examine
this further we determined how loss of WDR81 affected
the delivery of endocytosed fluorescent dextran to Magic
Red-positive, cathepsin-active organelles using a pub-
lished assay, previously used to show the requirement for
mammalian homologs of the HOPS complex in delivery
of endocytosed dextran to cathepsin-active lysosomes
(60,61). Using the control, WDR81KO and rescued
(2×HA-WDR81 complemented) HeLa cell lines described
in Figures 2E and F, we observed a reproducible reduction
in delivery of dextran to Magic Red-positive organelles in
WDR81KO HeLa cells, that was clearly rescued by expres-
sion of WDR81 cDNA (Figure 4F and G). These data are
consistent with a requirement for WDR81 in the matura-
tion of endosomal compartments and/or an impairment in
the delivery of cargo to late endolysosomal compartments.
WDR81 depletion inhibits the degradation of EGFR
by sequestering it in early endosomal compartments
Because the depletion of WDR81 affected endolyso-
somal maturation and the delivery of tetherin to late
endolysosomes, we wanted to determine whether WDR81
depletion also affects the degradation of other cell surface
proteins. We therefore examined the trafficking of the
well-characterized EGFR, which is phosphorylated upon
EGF ligand binding, rapidly endocytosed and trafficked
to lysosomes. The degradation of endocytosed EGFR
was examined in control and WDR81KO HeLa cells by
pulsing cells with EGF, chasing for the specified times
and immunoblotting solubilized cells for phosphorylated
EGFR (pEGFR) (Figure 5A). In WDR81-depleted cells we
observed a delay in the degradation of pEGFR (Figure 5B).
In the absence of WDR81, delayed EGFR degradation was
also observed using confocal microscopy of EGF-Alexa
555 pulsed cells (Figure S4).
Having shown that in WDR81KO cells tetherin accumu-
lates in early EEA1 positive endosomal compartments
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(Figure 4E and S3C), we next asked whether the delay in
EGFR degradation seen in WDR81KO cells (Figure 5A
and B) is due to EGFR accumulation in EEA1 posi-
tive endosomes. An accumulation of EGF-Alexa-555
bound EGFR in EEA1 positive compartments was seen in
WDR81-depleted cells (Figure 5C and D), consistent with
a defect in exit from EEA1 positive endosomes. Taken
together, Figure 4E, S3C, 5C and D suggest that depletion
of WDR81 delays exit of endocytosed cargo from early
endosomal compartments.
WDR81 function is dependent on interaction
with WDR91
To determine if WDR81 acts alone, or in complex with
other proteins, we used immunoprecipitation and mass
spectrometry to identify binding partners of WDR81.
Immunoprecipitation ofHA-taggedWDR81 fromWDR81
knockout HeLa cells complemented with 2×HA-WDR81
was performed. After subtracting proteins also present
in control immunoprecipitates, WDR91 was identified
as a WDR81 interaction partner (with 12 unique pep-
tides, Figure 6A). WDR91 is a 747 amino acid protein
whose bioinformatic analysis revealed 7 C-terminalWD40
domains. To determine whether the interaction between
WDR81 and WDR91 was of functional importance we
used the CRISPR-Cas9 system and three WDR91 sgRNAs
to generate independent WDR91 deficient cell lines. In
each of these cell lines, we observed accumulation of teth-
erin in swollen endolysosomes, identical to those seen fol-
lowing depletion of WDR81 (Figure 6B). The depletion of
WDR81 together with WDR91 did not exacerbate teth-
erin accumulation (Figure 6C). Furthermore, we observed
enlargement of both early EEA1 positive and late LAMP1
positive endolysosomal compartments inWDR91depleted
cells (Figure 6D), as seen inWDR81KO cells. Interestingly,
a C-terminal GFP fusion, which rendered an exogenous
WDR81 construct non-functional (i.e. unable to rescue
tetherin accumulation in WDR81KO cells, Figure S5A),
was unable to bind WDR91 (Figure S5B). Taken together,
the data shown in Figures 6 and S5 suggest that interaction
of WDR81 and WDR91 is critical for function.
Discussion
In this study, our forward genetic screen identified a
requirement forWDR81 in the HIV-Vpu-mediated degra-
dation of tetherin. Subsequent experiments showed that
WDR81 may play a more general role in the degrada-
tion of internalized PM proteins, that is independent of
HIV-Vpu. The degradation of both tetherin and pEGFR
was delayed in WDR81-depleted cells with both tetherin
and EGFR accumulating in enlarged, early, EEA1 posi-
tive endosomes. WDR81 associates with both early and
late endolysosomal compartments and the loss of WDR81
affected the morphology of the endolysosomal pathway
with the appearance of swollen early and late compart-
ments.This was accompanied by impaired delivery of fluid
phase dextran cargo to cathepsin-active lysosomes. Never-
theless, lysosomes of WDR81-depleted cells were able to
acidify and contained functional lysosomal proteases. We
also found that WDR81 forms a complex with WDR91,
which is required for correct function of these proteins.
Our data suggest that the WDR81-WDR91 complex is
required for the trafficking and degradation of internalized
PM proteins and facilitates delivery of cargo from early to
late endosomal/lysosomal compartments. Our findings are
consistent with a recent report from Liu et al. (72), pub-
lished during preparation of our manuscript, which iden-
tified the Caenorhabditis elegans orthologues of WDR81
and 91 (respectively F25C9.1 or SORF-2 and ZK563.5
Figure 4: WDR81 depletion alters endolysosomal morphology and trafﬁcking, and promotes the accumulation of
tetherin in swollen EEA1 positive vesicles. A) Confocal immunostaining of tetherin (red) in WDR81KO HeLa cells loaded with
dextran Alexa Fluor 488 (green) for 16 h. B–C) Confocal microscopy images of early (B) and late (C) endolysosomal markers in
control and WDR81KO HeLa cells. D) Confocal live microscopy of control and WDR81KO cells incubated with Magic Red. E) Confocal
immunostaining of tetherin (red), EEA1 (green) and LAMP1 (blue) in WDR81 KO cells. F) Representative live-cell confocal microscopy
images of control, WDR81 and 2×HA-WDR81 complemented WDR81KO HeLa cells that had been loaded with dextran Alexa Fluor 488
(green) for 2 h, chased for 1 h and then stained with Magic Red (red). G) Quantiﬁcation of colocalization of dextran Alexa Fluor 488 with
Magic Red using images captured by live-cell confocal microscopy of the cells in ‘F’. Mean± SEM of three independent experiments
with ﬁve ﬁelds each, ≥30 cells total per condition. *p≤ 0.05. All scale bars represent 5 μm.
Trafﬁc 2016; 17: 940–958 949
Rapiteanu et al.
Figure 5: Legend on next page
950 Trafﬁc 2016; 17: 940–958
The WDR81-WDR91 Complex Regulates Protein Trafﬁcking
or SORF-1), as genes required for partial rescue of the
endosome/lysosome fusion defects present in coelomo-
cytes of C. elegans vps18 mutants and showed that mam-
malian WDR81 and WDR91 form a complex functioning
in endolysosomal trafficking.
The development of forward genetic screens in haploid
human cells (73) provides a powerful approach to dissect
cellular pathways in mammalian systems. Initially used
in lethality screens (52,73,74), this approach has more
recently been applied to the selection of either cell surface
or intracellular phenotypes (53–55,75), and was used here
to identify components of the endocytic machinery. To
effectively enrich for the desired cellular phenotype may
require at least two FACS selections and is therefore depen-
dent on preserving cell viability throughout the timescale
of the selection process, which may be up to 28 days.
HIV-Vpu degrades CD4 from the early secretory pathway
via the cellular ERAD machinery, while degradation of
tetherin and SNAT1 occurs in the late secretory pathway.
Our genetic approach was successful in identifying critical
host cell components, including the E3 ligase βTrCP2,
required for Vpu-mediated CD4 downregulation, but the
identification of cellular genes required for Vpu-mediated
downregulation of tetherin proved more challenging
as the cells only survived a single round of positive
FACS-selection. The reasons for this are not entirely clear,
but suggest that cells may be less tolerant of perturbations
in the late as compared with the early secretory pathway.
Despite the selection for tetherinhigh-expressing cells only
surviving a single enrichment, our screen identified four
significant genes which function in the endocytic pathway
(Figure 1B). VPS33a and VPS39 are components of the
HOPS complex (56–58), which function in endosomal
maturation (59), delivery of cargo to lysosomes (60,61) and
fusion of autophagosomes with late endosomes/lysosomes
(62), and are therefore promising candidates for inter-
ference with tetherin downregulation and degradation.
Furthermore, siRNA-mediated depletion of the HOPS
components VPS33a (76) and VPS41 (77,78) impairs
degradation of EGFR.
We focussed on the top hit of our screen, as WDR81 is
a poorly characterized protein and one of nine BEACH
domain containing proteins (BDCP) [reviewed in (68)].
The BEACH domain was initially identified as a con-
served region within LYST but its exact function remains
unclear. Unlike other BDCPs which have a C-terminus
proximal BEACHdomain preceded by a pleckstrin homol-
ogy (PH) domain, the BEACH domain of WDR81 is
close to the N-terminus with no predicted PH domain
(Figure 3A). As its name implies, WDR81 has multiple
WD40 repeat (WDR) domains known to form scaffolds
on which large protein complexes assemble [reviewed in
(79,80)]. Although WDR81 was earlier suggested being
an integral membrane spanning protein (69), both our
bioinformatic and biochemical (Figure 3B) analysis sug-
gest that WDR81 is cytosolic and it associates with EEA1
positive and LAMP1 positive endosomal membranes. This
is in agreement with the recent findings of Liu et al. (72)
who showed the association/colocalization ofWDR81with
EEA1- and Rab7-positive endosomes.
The depletion of WDR81 led to only a modest increase in
cell surface tetherin, but a marked accumulation of intra-
cellular tetherin that was apparent in both Vpu-sufficient
and Vpu-deficient cells. Taken together, our results suggest
that this is due to a perturbation in delivery of endocytosed
cargo to lysosomes caused by accumulation of cargo in
Figure 5: WDR81 depletion delays EGFR degradation and promotes EGFR accumulation in early EEA1 positive
endosomal compartments. A) Control, WDR81KO and baﬁlomycin A (400 nM) treated control cells were stimulated with EGF
for the indicated times and analysed using immunoblot for phosphorylated EGFR (pEGFR). CNX, calnexin. B) pEGFR signal from three
replicates of the experiment shown in ‘A’ was quantiﬁed using Image J, normalized by loading and the average normalized pEGFR levels
from control and WDR81KO cells were plotted to reﬂect percentage of normalized pEGFR at 45min ±SEM. C) Confocal microscopy of
control and WDR81KO HeLa cells stimulated with EGF-Alexa-555 for 5 min (red) and chased for the indicated times. Cells were then
ﬁxed and stained for EEA1 (green). Scale bars represent 10 μm. D) Quantiﬁcation of colocalization (normalized to the 20min time
point) of EGF-Alexa-555 with EEA1 using images captured by live-cell confocal microscopy of the cells in ‘C’. Mean± SEM of three
independent experiments with ≥5 ﬁelds (average two cells per ﬁeld) each per condition. Scale bars represent 5 μm.
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Figure 6: WDR81 forms a functional complex with WDR91. A) Mass spectrometry analysis of 2×HA-WDR81 immunoprecipi-
tates from 2×HA-WDR81 expressing HeLa cells as compared with wild-type control HeLa cells identiﬁes WDR91 as a WDR81 binding
partner. B) WDR91 was depleted in HeLa cells by stable expression of Cas9 and three independent WDR91-speciﬁc sgRNAs. Tetherin
trafﬁcking in the resulting WDR91 KO cell lines and controls was analysed using confocal immunostaining. Scale bars represent 10 μm.
C) WDR91 was depleted in WDR81KO clones and tetherin distribution was imaged using confocal microscopy. Scale bars represent
10 μm. D) Confocal microscopy images of early EEA1 positive and late LAMP1 positive endolysosomal compartments in control and
WDR91 depleted HeLa cells. Scale bars represent 5 μm.
early endosomal compartments. The recent findings of
Liu et al. (72) provide important mechanistic insight into
our own observations on the defect of tetherin trafficking
and degradation seen in WDR81- and WDR91-depleted
cells. They showed that WDR81 and WDR91 were able to
regulate phosphatidylinositol 3-phosphate (PtdIns3P) lev-
els on endosomal membranes. Consequently, depletion of
WDR81 and WDR91 led to the accumulation of PtdIns3P
on early endosomal membranes, which caused exces-
sive fusion of early endosomes and delayed early-to-late
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endosome conversion (72). Indeed, delayed traffick-
ing of endocytosed fluid phase markers and altered
endolysosomal morphology with enlarged early and
late endolysosomal compartments was observed in
WDR81-depleted mammalian cells [present study and
(72)] as well as in F25C9.1 (WDR81 ortholog) depleted
C. elegans coelomocytes, suggesting that this phenotype
is evolutionarily conserved from C. elegans to humans.
Although Liu et al. also observed that theWDR81-WDR91
complex interacts with Beclin1 to inhibit the phos-
phatidylinositol 3-kinase complex (72), we did not detect
Beclin1 in our WDR81 mass spec IP suggesting that this
interaction might be relatively weak.
Mutations in several BDCPs cause human disease
[reviewed in (68)] and WDR81 is no exception. The
P856L mutation in WDR81 is associated with cerebellar
ataxia, mental retardation, and disequilibrium syndrome
2 (CAMRQ2) (69). It would therefore be interesting to
determine whether this mutation causes the same pheno-
type as WDR81 depletion or whether P856L acts as a gain
of function mutation. Because the mutation occurs in the
central region of WDR81, further studies should aim to
identify whether it abolishes binding to WDR91.
In summary, we have shown a critical role for the
WDR81-WDR91 complex in facilitating endosomal mat-
uration and delivery of cargo to late endolysosomes. Fur-
thermore, our results provide evidence for the role of the
WDR81-WDR91 complex in facilitating the downregula-
tion and subsequent degradation of cell surface receptors.
Materials and Methods
Plasmids
Codon optimized NL4-3 Vpu was subcloned from pCR3.1-Vpu-
HA (38) into the lentiviral expression vector pHRSIN-Rox-PSFFV-GFP-
PPGK-puromycinR-Rox (54) in place of the GFP. The resulting
plasmid was further modified downstream of Vpu with an inter-
nal ribosome entry site (IRES) CFP to generate the pHRSIN-Rox-
PSFFV-Vpu-IRES-CFP-PPGK-puromycinR-Rox expression vector.
C terminally GFP taggedWDR81was subcloned from the pCS2-WDR81-
GFP construct (Creative Biogene) into the pHRSIN-PPGK-blasticidinR
background to generate pHRSIN-PSFFV-WDR81-GFP-PPGK-blasticidinR.
The construct was further modified to accommodate a double HA
tag at the N terminus of WDR81 thus generating pHRSIN-PSFFV-
2xHA-WDR81-PPGK-blasticidinR.
Streptococcus pyogenes Cas9 was subcloned from the PX458 plasmid
[Addgene; created by Feng Zhang, Massachusetts Institute of Technology,
Boston, MA (81)] into a pHRSIN backbone creating pHRSIN-PSFFV-
FLAG-NLS-Cas9-NLS-PPGK-hygromycinR. Short guide RNAs (sgRNA)
were expressed from the pKLV-U6gRNA(BbsI)-PGKpuro2ABFP
plasmid [Addgene; created by Kosuke Yusa, Wellcome Trust Sanger
Institute, Hinxton, Cambridge, UK (82)] targeting WDR81 and WDR91,
respectively. Specific sgRNA sequences used: WDR81 sgRNA#1
5′-AGGTGGCCACGGGCTCGCTC-3′ (exon 5); WDR81 sgRNA#2
5′-CCTCATGGCTGATCCGGGGC-3′ (exon 4); WDR91 sgRNA#1
5′-CAGCTCGTCAGTGCGCTCCA-3′ (exon 1); WDR91 sgRNA#2
5′-GTAGCTCCAATAATCCCGAA-3′ (exon 2); WDR91 sgRNA#3
5′-GTCTGTATATATCCTCCAAG-3′ (exon 2); All plasmids were
sequenced by Source Bioscience.
Cell lines
KBM7, CEMT4 and HeLa cells were maintained in IMDM supplemented
with 10% foetal calf serum and penicillin/streptomycin. Stable cell lines
were produced by lentivirus transduction. Lentivirus was produced by
cotransfecting 293ET cells with lentiviral vectors alongwith the packaging
plasmids pCMVΔR8.91 and pMD.G using TransIT-293 (Mirus) accord-
ing to the manufacturer’s instructions. Viral supernatant was harvested
48 h post-transfection, filtered and transferred to cells, followed by spin
infection at 1800 rpm for 45min.
Antibodies
Mouse anti-Tetherin (APC coupled, BioLegend, 348410) and mouse
anti-CD4 (PE coupled, BioLegend, 300508) were used for flow-cytometry
and FACS. Antibodies used for immunoblotting include: rabbit
anti-WDR81 (Abcam, ab1217333, LOTGR98370-3); rabbit anti-Tetherin
[NIH AIDS Reagent Programme, 11721, LOT 110114, (83)]; rabbit
anti-Phospho-EGF Receptor (Cell Signalling, 2234); mouse anti-MHC-I
heavy chain (clone 3B10.7);mouse anti-FattyAcid Synthase (BD, 610962);
mouse anti-α-tubulin (Sigma, T9026); mouse anti-ß-actin (Sigma,
A2228); mouse anti-calnexin (BD, 610962); goat anti-mouse-HRP
(Jackson ImmunoResearch, 115-035-062) and goat anti-rabbit-HRP
(Jackson ImmunoResearch, 111-035-144). Antibodies used for confocal
microscopy: rabbit anti-Tetherin [NIH AIDS Reagent Programme,
11721, LOT 110114, (83)]; mouse anti-HA (BioLegend, 901502);
mouse anti-EEA1 (BD, 610457); mouse anti-Rab5 (BD, 610724);
mouse anti-CD63 (BD, 556019); mouse anti-LAMP1 (BD, 555798);
mouse anti-LAMP1 (Alexa Fluor 647 conjugated, BD, 562622); rabbit
anti-Cathepsin D (Millipore, 219361); donkey anti-rabbit IgG (Alexa
Fluor 488 conjugate, Thermo Fisher Scientific, A-21206); donkey
anti-mouse IgG (Alexa Fluor 647 conjugate, Thermo Fisher Scientific,
A-31571); goat anti-mouse IgG (Pacific Blue conjugate, Thermo Fisher
Scientific, P31582).
Haploid genetic screen
The screen followed previously described protocols (53) with a number
of adjustments. Firstly, to avoid potential artefacts associated with single
proviral integration sites, we pooled three Vpu-IRES-CFP KBM7 clones
Trafﬁc 2016; 17: 940–958 953
Rapiteanu et al.
that express low PM levels of both Tetherin and CD4 and expanded
them to 100 million cells prior to mutagenesis. The gene-trap vector used
resembles the previously described pGT-GFP-pA (75), with the exception
of a loxP cassette which was subcloned into the 3′ LTR. One week
post-mutagenesis, cells were selected for either Tetherinhigh or CD4high.
The collected CD4high population was subjected to a second enrichment
prior to genomic DNA extraction. For the tetherinhigh screen, genomic
DNA was extracted from the cells recovered after the first sort. Gene-trap
integration sites weremapped and processed as previously described (53).
Flow cytometry
Cells were washed in PBS and, if necessary, detached by trypsinization.
Routinely, 5× 105 cells were incubated for 30min at 4∘C in 100 μL PBS
with the indicated fluorochrome-conjugated antibody or stained sequen-
tially with primary and fluorochrome-conjugated secondary antibodies.
Following fixation with 4% paraformaldehyde (PFA), cells were analysed
on a Fortessa (BD). Data were analysed with the FlowJo software.
CRISPR/Cas9-mediated gene disruption
Cells stably expressing Cas9 and WDR81 or WDR91 specific sgRNAs
were created by cotransfection of Cas9, sgRNA plasmids and packaging
plasmids in 293ET, following the same protocol used for the generation
of stable cell lines. WDR81 depletions by transient Cas9 and sgRNA
expression were generated by cotransfecting HeLa cells with the Cas9
andWDR81 sgRNA#1 plasmids using TransIT-HeLaMONSTER (Mirus)
according to the manufacturer’s instructions. After 24 h of transfection,
cells were enriched for 72 h by puromycin and hygromycin selection and
then single cell cloned. WDR81 knockout clones were identified using
Immunoblot.
Immunoblotting
Cells were washed in PBS and, if necessary, detached by trypsinization
and lysed in 1% Triton X-100 in TBS with 0.5mM phenylmethylsulfonyl
fluoride (PMSF), 10mM iodoacetamide (IAA), and Roche complete pro-
tease inhibitor for 30min on ice. Post-nuclear supernatants were heated
at 40∘C for 20min in SDS sample buffer, separated by SDS-PAGE, and
proteins transferred to PVDF membranes (Milipore). Membranes were
blocked in 5% milk (Marvel) in PBS/0.2% Tween and probed with the
indicated antibodies. Reactive bands were visualized using SuperSignal
West Pico chemiluminescent substrate (Thermo Fisher Scientific). To
quantitate protein levels, X-ray films were scanned and subjected to den-
sitometric analysis using ImageJ. Signal was then normalized by exposure
and loading control prior to plotting on bar charts. Error bars represent
the SEM for three technical repeats. Statistical significance was evaluated
by paired, two-tailed t-tests.
Confocal microscopy
Cells were grown overnight on round 13mm glass coverslips, fixed in 4%
PFA and permeabilized with 0.5%Triton X-100, each step followed by two
PBS washes. Where indicated, HeLa cytosol was extracted by incubating
cells for 40 second in PBS containing 0.05% saponin and then immedi-
ately formaldehyde fixed. Cells were then blocked for 30min with 5%
FCS in PBS and incubated with primary antibody for 45–60min at room
temperature. Following threewashes in blocking buffer, fluorescently cou-
pled secondary antibody was applied for 30min. After three washes in
blocking buffer and three washes in water, coverslips were mounted in
ProLong Gold Antifade Mountant with DAPI (Thermo Fisher Scientific)
and imaged on a Zeiss LSM880 Confocal Microscope. Images were pro-
cessed using the Zen 2011 software (Zeiss).
EGFR degradation assay
For quantification by immunoblot, cells were incubated in HBSS
amino acid depleted media (Thermo Fisher Scientific, 24020117) with
10 μg/mL cycloheximide and, where indicated, with 400 nM bafilomycin
A (Sigma-Aldrich) for 1 h prior to continuous stimulation with EGF
(100 ng/mL) for the indicated times. Cells were then lysed and processed
as described above.Three experimental repeats were subjected to densito-
metric analysis using the ImageJ software.The resulting plot was adjusted
to reflect mean percentage of normalized pEGFR levels at 45min± SEM.
For visualization of endocytosed EGFR by confocal microscopy, cells
seeded on cover slipswere amino acid starved for 1 h prior to a 5min incu-
bation with EGF-Alexa-555 (Thermo Fisher Scientific, E-35350) on ice.
Cells were then washed twice in cold PBS and incubated at 37∘C for the
indicated times. Cells were then fixed in 4% PFA, washed, EEA1 stained
and mounted. Single confocal images were acquired as described above
(three independent experiments with ≥5 fields each per condition, aver-
age of two cells per field, randomly selected).The degree of colocalization
between EGF-Alexa-555 and EEA1 was measured by Manders M1/M2
colocalization coefficients using the ZEN 2011 software (Zeiss) and nor-
malized to the 20min time point. Peak colocalization between EEA1 and
EGFR was previously reported at 15min (84,85). In this study, we incu-
bated a further 5 min at 37∘C (total 20min) to allow cells to equilibrate
after pulsing on ice.
Dextran, Magic Red and Lysosensor labelling
To label the endocytic pathway with dextran, cells were loaded for 16 h
with 1mg/mL dextran Alexa Fluor 488 10 000MW, anionic (Thermo
Fisher Scientific, D-22910), washed, fixed, permeabilized and stained for
intracellular tetherin as described above. To label endosomal/lysomal
compartments containing the active acid hydrolase cathepsin B, live cells
on coverslips were incubated for 5min at 37∘CwithMagic RedMR-(RR)2
Cathepsin B substrate (1:2600 dilution) (ImmunoChemistry Technolo-
gies, 938) and then imaged on an incubated Zeiss LSM710 Confocal
Microscope. To assess acidic organelles, cells were labelled with LysoSen-
sor Yellow/Blue DND-160 (Thermo Fisher Scientific, L-7545), a ratiomet-
ric probe that produces blue fluorescence in a neutral environment but
shifts to yellow fluorescence in more acidic compartments (pKa≈ 4.2).
Cells were incubated for 1min at 37∘C with LysoSensor and then imaged
on an incubated Zeiss LSM710 Confocal Microscope. Cells were excited
at 405 nm and images were taken at 455.5± 32.5 and 570.5± 70.5 nm of
emission. Zen 2011 (Zeiss) and ImageJ software were used for the analy-
sis and processing of confocal images. The graph shows the mean value
with the standard error mean of the yellow/blue ratios obtained from
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three experimental repeats (20 cells spread across 4 confocal fields for each
experimental condition).
Delivery of endocytosed dextran to lysosomes
Apreviously described protocol was used tomeasure the delivery of endo-
cytosed dextran to lysosomes by quantitative live cell confocalmicroscopy
(61). Briefly, HeLa cells were loaded for 2 h with 1mg/mL Dextran Alexa
Fluor 488 10 000MW, anionic, fixable (Thermo Fisher Scientific) and then
chased for 1 h in dextran-free IMDM. Cells were then washed in PBS
and incubated with Magic Red MR-(RR)2 Cathepsin B substrate (1:2600
dilution) (ImmunoChemistry Technologies). Single confocal images were
acquired using an incubated Zeiss LSM710 Confocal Microscope (three
independent experiments with ≥5 fields each per condition, average
of 1–2 cells per field, randomly selected). The degree of colocalization
between Dextran Alexa Fluor 488 and Magic Red was measured by Man-
ders M1/M2 colocalization coefficients using the ZEN 2011 software
(Zeiss).
Immunoprecipitation and mass spectrometry
Cells were lysed in 1% Triton X-100 or 1% NP-40 in TBS with 0.5mM
PMSF, 10mM IAA and Roche complete protease inhibitor for 30min
on ice. Post-nuclear supernatants were pre-cleared with protein A and
IgG-Sepharose (Sigma-Aldrich) and incubatedwith EZviewRedAnti-HA
Affinity Gel (Sigma-Aldrich) or anti-GFP (Roche, 11814460001) plus
protein A sepharose for 4 h at 4∘C. Following one wash in 1% and four
washes in 0.5% lysis buffer, immunoprecipitated proteins were eluted in
Lamelli buffer. Samples were then resolved by SDS-PAGE, gel lanes were
excised and proteins were digested in-gel. Tryptic peptides were analysed
by LCMS/MS and the raw files processed in Proteome Discoverer 1.4.
Data were searched using Mascot against the Human Uniprot database
including common contaminants and a randomised reverse database.
Results were filtered to a PSM FDR of 1%.
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Figure S1. Haploid genetic screen is validated by the identification of
components of the SCF𝛃TrCP2 E3ubiquitin ligase complex, known to be
required for Vpu-mediated downregulation of CD4 and degradation
of CD4 and tetherin. A) Schematic view of the Vpu IRES CFP construct.
B) Schematic of sorting gates designed to avoid selection of rare cells that
have lost Vpu expression (shown inside the yellow dashed oval). C) Bubble
plot illustrating the hits from the CD4high screen. Bubble size is propor-
tional to the number of independent inactivating gene-trap integrations
identified (shown in brackets). D–E) Cytofluorometric analysis of teth-
erin and CD4 in control, Vpu expressing and Vpu expressing βTrCP2/1
depleted KBM7s (D) and CEMT4 (E) cells.
Figure S2: Cell surface tetherin levels are partially rescued by WDR81
depletion in CEMT4 and HeLa cells. A) Cytofluorometric analysis of
cell surface tetherin expression in CEMT4 T cells: wild-type (WT – blue
dotted histogram), Vpu-expressing (Vpu – red dotted histogram) and
Vpu-expressing CEMT4 cells depleted of WDR81 (KO – orange shaded
histograms) by stable expression of two independent sgRNAs. Num-
ber in black represents median fluorescence signal. B) Median plasma
membrane tetherin signal from three independent experiments using
cells in ‘A’ was plotted± SEM. * p ≤ 0.05. C) Cytofluorometric analysis
of cell surface tetherin expression in HeLa cells: wild-type (WT – blue
dotted histogram), Vpu expressing (Vpu – red dotted histogram) and
Vpu-expressing HeLa cells depleted of WDR81 (KO – orange shaded
histogram). Number in black represents median fluorescence signal. D)
Immunostaining of tetherin in wild-type and Vpu-expressing HeLa cells.
Showing the same images as in Figure 2D (left panels) with increased
contrast in the tetherin channel. Processed with ZEN 2011. Scale bars rep-
resent 10 μm.
Figure S3: Depletion ofWDR81 does not impede endolysosomal acid-
ification. Tetherin accumulates in early EEA1 positive but not in late
LAMP1 positive compartments. A) Control and WDR81KO cells were
labelled with LysoSensor Yellow/Blue DND-160, a ratiometric probe that
produces blue fluorescence in a neutral environment (green) but shifts
to yellow fluorescence in more acidic compartments (red). B) Averages
of yellow/blue ratios obtained from three experimental repeats (20 cells
spread across 4 confocal fields for each experimental condition)were plot-
ted± SEM. **p≤ 0.01. C) Immunostaining of tetherin and EEA1 in con-
trol and WDR81KO cells. D) Immunostaining of tetherin and LAMP1 in
control and WDR81KO cells. All scale bars represent 5 μm.
Figure S4: WDR81 depletion delays EGFR degradation. Confocal
microscopy of control and WDR81KO HeLa cells stimulated with
EGF-Alexa 555 and chased for the indicated times. Detector gain was
decreased 1.25-fold for the 20, 60 and 180 min time points (as compared
to 0 min). Scale bars represent 10 μm.
Figure S5: C-terminalGFP fusion rendered an exogenousWDR81 con-
struct non-functional and unable to bind WDR91. A) Immunostain-
ing of tetherin in WDR81-GFP complemented WDR81KO cells. Scale
bars represent 10 μm. B) Mass spectrometric analysis of WDR81-GFP
immunoprecipitates. Wild-type HeLa cells were used as control.
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